About AVT
Browse Articles
Customer Services


Potential threat of drug-resistant and vaccine-escape HBV mutants to public health

Chong-Gee Teo, Stephen A Locarnini

Corresponding author name: Chong-Gee Teo
Corresponding author e-mail: enz0@cdc.gov

Citation: Antiviral Therapy 2010; 15:445-449
doi: 10.3851/IMP1556

Date accepted: 22 February 2010
Date published online: 28 May 2010


Immune pressure exerted on HBV by anti-HBV antibodies and long-term therapy with drugs that mutagenize the viral P gene can select for mutations in its S gene, leading to vaccine escape and evasion from serological detection. Although transmissibility of these mutants is poor and their evolution towards heightened virulence appears slow, the situation could change as vaccination coverage increases, and treatment of patients with chronic hepatitis B and those coinfected by HIV and HBV becomes widespread. Enhanced surveillance programmes to track changes in the genotype and phenotype of the mutants are needed.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.